AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Cinmove RTU 100mg Injection

Prescription Icon
Prescription Required

Marketer

Cipla Ltd

Salt Composition

Remdesivir (100mg)

Overview Cinmove RTU 100mg Injection

Remdesivir 100mg Ready-to-Use Injection is a wide-ranging antiviral medication indicated for hospitalized adults and children with severe, confirmed or suspected COVID-19. This treatment reduces the viral burden, accelerating recovery. Its mechanism involves blocking RNA polymerase, a crucial enzyme for SARS-CoV-2 replication. Administered intravenously under medical supervision, Remdesivir 100mg requires a doctor's prescription and adherence to the prescribed dosage and duration. Self-administration is strictly prohibited. Common adverse effects include elevated blood glucose, anemia, fever, acute kidney impairment, and increased liver enzymes. Report any allergic reaction or concerning side effect to your physician. Disclose pregnancy or breastfeeding to your doctor. Use caution when administering to elderly or pediatric patients.

Primary Ingredients of Cinmove RTU 100mg Injection

No text was provided to rewrite.

Uses of Cinmove RTU 100mg Injection

Managing the Coronavirus (COVID-19) infection

Major Benefits of Cinmove RTU 100mg Injection:

This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.

Common Side effects of Cinmove RTU 100mg Injection:

  • Headache
  • Rash
  • Extravasation
  • Increased prothrombin time
  • Increased transaminase level in blood

How to use Cinmove RTU 100mg Injection:

Administering this medication will be performed by your healthcare provider. Self-medication is strongly discouraged.

How Cinmove RTU 100mg Injection works:

Cinmove RTU 100mg Injection is a wide-ranging antiviral medication. Its mechanism involves blocking RNA polymerase, an RNA-dependent enzyme crucial for SARS-CoV-2 replication. This action effectively reduces the virus's concentration within the patient.

SAFETY ADVICE

AlcoholAlcoholCONSULT YOUR DOCTOR

The safety of combining alcohol with Cinmove RTU 100mg Injection is undetermined. Seek medical advice before doing so.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Cinmove RTU 100mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any possible risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Administration of Cinmove RTU 100mg Injection while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

The effect of Cinmove RTU 100mg Injection on driving ability is undetermined. Refrain from driving if experiencing symptoms impairing concentration or reaction time.

KidneyKidneyCONSULT YOUR DOCTOR

Data regarding the use of Cinmove RTU 100mg Injection in patients exhibiting renal impairment is scarce. Physician consultation is advised.

LiverLiverCONSULT YOUR DOCTOR

Insufficient data exists regarding the administration of Cinmove RTU 100mg Injection to individuals with hepatic impairment. Physician consultation is advised.

What if you forget to take Cinmove RTU 100mg Injection :

NA

Facts to Know About Cinmove RTU 100mg Injection

LabelValue
Chemical Type Amino acid alkyl esters
Developing Habits No.
Treatment Category Antimicrobial Agents

FAQs on Cinmove RTU 100mg Injection

COVID-19, or coronavirus disease 2019, is a novel lung infection caused by the SARS-CoV-2 virus. This highly contagious virus spreads rapidly between individuals. Common symptoms include fever, cough, and shortness of breath.
Cinmove RTU 100mg Injection, an antiviral medication, demonstrated effectiveness in managing severe COVID-19 in recent laboratory studies of hospitalized patients. While not approved for COVID-19 treatment, some studies indicate faster recovery in patients treated with Cinmove RTU 100mg Injection compared to other treatments. However, its safety and efficacy in treating COVID-19 require further investigation, with ongoing clinical trials underway.
The Food and Drug Administration (FDA), under the authority of the Food, Drug, and Cosmetic Act, issues Emergency Use Authorizations (EUAs) for medical products—including medicines, vaccines, and devices—to combat serious threats to public health, such as the COVID-19 pandemic. An EUA allows use of a product before full approval, balancing potential benefits against known risks.
Cinmove RTU 100mg Injection is administered intravenously only in hospitals, by a doctor, to hospitalized children and adults with severe COVID-19. Severe COVID-19 is defined as SpO2 ≤94% on room air, or requiring supplemental oxygen, mechanical ventilation, or ECMO. Self-administration is strictly prohibited. Always follow your doctor's instructions for optimal results.
The European Medicines Agency (EMA) has authorized Cinmove RTU 100mg Injection for use in hospitalized patients with severe COVID-19, exhibiting faster recovery in adults and children experiencing severe respiratory distress.
Clinical trials are ongoing for Cinmove RTU 100mg Injection. Early findings show it inhibits SARS-CoV-2 replication, reducing viral load and potentially accelerating recovery from COVID-19.
Cinmove RTU 100mg Injection may cause anemia, fever, kidney damage, nausea, vomiting, chills, sweating, low blood pressure, and elevated liver enzymes. Further research is needed to fully understand its side effects, especially given its ongoing evaluation for COVID-19 treatment. Consequently, additional risks associated with Cinmove RTU 100mg Injection are possible.
Insufficient data exists to confirm the safety and efficacy of Cinmove RTU 100mg Injection for treating hospitalized adults and children with severe COVID-19. Its use in such patients is conditional, balancing potential benefits against known and unknown risks. Ongoing clinical trials are investigating its safety profile.
Limited data exists on Cinmove RTU 100mg Injection's use in COVID-19 treatment. Its safety and effectiveness in pregnant or breastfeeding women are unknown. If pregnant, breastfeeding, or planning pregnancy, consult your doctor immediately if you have or suspect COVID-19. They will determine the appropriate course of action based on your individual circumstances.
Inform your doctor of all medical conditions, including kidney or liver problems, serious illnesses (like heart disease or diabetes), and allergies, before receiving Cinmove RTU 100mg Injection. Disclose all medications you're taking—prescription, over-the-counter, vitamins, or herbal products—as Cinmove RTU 100mg Injection may interact with them. Specifically mention any medicines containing chloroquine phosphate or hydroxychloroquine sulfate. Also, tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Cinmove RTU 100mg Injection is not approved for COVID-19 prevention; its efficacy in this context is unsupported by evidence.
The Drug Controller General of India (DCGI) has granted emergency authorization for Cinmove RTU 100mg Injection due to the pandemic. Its use is restricted to confirmed COVID-19 patients with a clinical indication; it is not for preventative or suspected cases.
Cinmove RTU 100mg Injecti...
2,430
MRP 2,813
13% off